inclusion criteria: - probable covid-19 based on presence of at least 5 of the following symptoms of acute onset within the prior 4 days: fever, cough, sore throat, fatigue, episodic chest pain or shortness of breath with exercise, muscle or body aches, headache, loss of smell or taste, stuffy or runny nose, chills or shivering, feeling hot or feverish, nausea, diarrhea - subjects must signify that they have contacted a doctor about their current symptoms. - subject gives informed consent for study and is willing to take the treatments and complete the scheduled evaluations. - subject has acquired a study partner who has agreed to complete the follow-up forms for the subject if the subject unable or has been hospitalized.

inclusion criteria: - probable covid-19 based on presence of at least 5 of the following symptoms of acute onset within the prior 4 days: fever, cough, sore throat, fatigue, episodic chest pain or shortness of breath with exercise, muscle or body aches, headache, loss of smell or taste, stuffy or runny nose, chills or shivering, feeling hot or feverish, nausea, diarrhea - subjects must signify that they have contacted a doctor about their current symptoms. - subject gives informed consent for study and is willing to take the treatments and complete the scheduled evaluations. - subject has acquired a study partner who has agreed to complete the follow-up forms for the subject if the subject unable or has been hospitalized.

inclusion criteria: 1. - probable covid-19 based on presence of at least 5 of the following symptoms of acute onset within the prior 4 days: fever, cough, sore throat, fatigue, episodic chest pain or shortness of breath with exercise, muscle or body aches, headache, loss of smell or taste, stuffy or runny nose, chills or shivering, feeling hot or feverish, nausea, diarrhea 2. - subjects must signify that they have contacted a doctor about their current symptoms. 3. - subject gives informed consent for study and is willing to take the treatments and complete the scheduled evaluations. 4. - subject has acquired a study partner who has agreed to complete the follow-up forms for the subject if the subject unable or has been hospitalized.

inclusion criteria: 1. - probable covid-19 based on presence of at least 5 of the following symptoms of acute onset within the prior 4 days: fever, cough, sore throat, fatigue, episodic chest pain or shortness of breath with exercise, muscle or body aches, headache, loss of smell or taste, stuffy or runny nose, chills or shivering, feeling hot or feverish, nausea, diarrhea 2. - subjects must signify that they have contacted a doctor about their current symptoms. 3. - subject gives informed consent for study and is willing to take the treatments and complete the scheduled evaluations. 4. - subject has acquired a study partner who has agreed to complete the follow-up forms for the subject if the subject unable or has been hospitalized.

inclusion criteria: 1. - probable covid-19 based on presence of at least 4 of the following symptoms of acute onset within the prior 4 days: fever, cough, sore throat, fatigue, episodic chest pain or shortness of breath with exercise, myalgia, headache, loss of smell. 2. - subjects must signify that they have contacted a doctor about their current symptoms. 3. - subject gives informed consent for study and is willing to take the treatments and complete the scheduled evaluations. 4. - subject has acquired a study partner who has agreed to complete the follow-up portion (part 2) of the study survey form for the subject if the latter unable or has been hospitalized, and who has agreed to buy the study agents (see criterion 6) for the subject if the latter is unable to at the start of the study. 5. - has already bought or is willing to buy a supply of nature made ascorbic acid of at least fifty 1000-milligram tablets or 100 500-mg tablets), famotidine (at least 50 20-mg tablets of pepcid ac), and nature made vitamin d3 (at least 60 2000-iu capsules).

inclusion criteria: 1. - probable covid-19 based on presence of at least 4 of the following symptoms of acute onset within the prior 4 days: fever, cough, sore throat, fatigue, episodic chest pain or shortness of breath with exercise, myalgia, headache, loss of smell. 2. - subjects must signify that they have contacted a doctor about their current symptoms. 3. - subject gives informed consent for study and is willing to take the treatments and complete the scheduled evaluations. 4. - subject has acquired a study partner who has agreed to complete the follow-up portion (part 2) of the study survey form for the subject if the latter unable or has been hospitalized, and who has agreed to buy the study agents (see criterion 6) for the subject if the latter is unable to at the start of the study. 5. - has already bought or is willing to buy a supply of nature made ascorbic acid of at least fifty 1000-milligram tablets or 100 500-mg tablets), famotidine (at least 50 20-mg tablets of pepcid ac), and nature made vitamin d3 (at least 60 2000-iu capsules).